Business
Cipher Pharmaceuticals Inc. announces Canadian launch of Actikerall(TM)
Cipher Pharmaceuticals Inc. announces Canadian launch of Actikerall™ Cipher...
About this update from Cipher Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCipher Pharmaceuticals Inc. announces Canadian launch of Actikerall™\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen3{\nBORDER-BOTTOM:black 0pt; TEXT-ALIGN: RIGHT; BORDER-LEFT:black 0pt; PADDING-LEFT:0.50em; PADDING-RIGHT:0.50em; VERTICAL-ALIGN: TOP; BORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt\n}\n.prngen4{\nBORDER-BOTTOM:black 0pt; BORDER-LEFT:black 0pt; PADDING-LEFT:0.50em; PADDING-RIGHT:0.50em; VERTICAL-ALIGN: BOTTOM; BORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt\n}\n.prnrbrb0{\nBORDER-RIGHT:black 0pt\n}\n.prnpr6{\nPADDING-RIGHT:0.50em\n}\n.prntal{\nTEXT-ALIGN: LEFT\n}\n.prnpl6{\nPADDING-LEFT:0.50em\n}\n.prnsbl0{\nBORDER-LEFT:0pt\n}\n.prnvat{\nVERTICAL-ALIGN: TOP\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n.prnsbb0{\nBORDER-BOTTOM:0pt\n}\n.prnsbt0{\nBORDER-TOP:0pt\n}\n.prnsblb0{\nBORDER-LEFT:black 0pt\n}\n.prnsbtb0{\nBORDER-BOTTOM:black 0pt\n}\n.prnsbr0{\nBORDER-RIGHT:0pt\n}\n\n\n\n\n\n\nCipher Pharmaceuticals Inc. announces Canadian launch of Actikerall™\nCanada NewsWire\nMISSISSAUGA, ON, Feb. 22, 2016\n\n\n\nMISSISSAUGA, ON, Feb. 22, 2016 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) (\"Cipher\" or \"the Company\") today announced the Canadian launch of Actikerall™ (0.5% fluorouracil and 10% salicylic acid), indicated for the topical treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp in immunocompetent adult patients1. Actinic keratosis, also known as solar keratosis, is a skin condition caused by exposure to ultraviolet radiation2. Cipher acquired Actikerall™ from Almirall S.A. in May, 2015. The product represents the third marketed product in Cipher's growing Canadian dermatology portfolio.\n\n\"We're excited to introduce Actikerall™ as a new treatment option for Canadians who suffer from actinic keratosis,\" said Shawn O'Brien, President & CEO of Cipher. \"Today, 60% of all Canadians2 over the age of 40 have at least one lesion, and it is expected that the incidence will increase as the population ages.\"\n\nJoan ...